Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target […]